The Years of the Monkey

The fact that mammals are diploid sets a barrier to rapidly understand the function of non-coding and coding genes in the genome. Recently, Yang et al. reported successful derivation of monkey haploid embryonic stem cells from parthenotes, which provide an effective platform for studying mammalian gene function and enable reverse genetic screening of genes for recessive phenotypes in monkeys.According to the Zodiac in the Chinese Calendar, the next year of the monkey is not slated until February 2016, but a recent paper in this month''s Cell Research suggests that it may have arrived early for the field of stem cell biology. In a stunning technical “Tour de Force”, Jinsong Li and his colleagues report for the first time the generation of several independent haploid monkey embryonic stem (ES) cell lines¹, building on the previous work from their lab and others that described the generation of murine haploid ES cell lines^2,3,4,5 (Figure 1). They first activated metaphase II monkey oocytes with ionomycin followed by cycloheximide treatment. These activated oocytes could develop into blastocysts in vitro and haploid ES cells (haESCs) can be derived by culturing the inner cell mass in a standard monkey ES cell culture system and using Hoechst FACS technique. Remarkably, one of the cell lines remained stable during long term passage, obviating the need for FACS sorting for the haploid cell lines during subsequent propagation. The cell lines can be genetically manipulated by insertional mutagenesis or by PiggyBac transposon technology, suggesting the possibility of genome-wide screening strategies. In this regard, a series of parallel scientific advances suggest that this technology platform may be particularly timely as the field of stem cell biology moves towards regenerative medicine and therapeutics.Open in a separate windowFigure 1The scheme of parthenogenetic (PG) and androgenetic (AG) haploid embryonic stem cells (haESCs) derivation. (A) For the generation of PG-haESCs, metaphase II oocytes were activated with either strontium chloride (SrCl₂) for mice or ionomycin/cycloheximide (CHX) for monkeys and further cultivated to the blastocyst stage. With the help of Hoechst FACS technique, PG-haESCs can be derived. (B) For the generation of AG-haESCs, metaphase II oocytes were enucleated followed by sperm injection. In addition, the reconstructed oocytes were activated with SrCl₂ for mice and further developed to the blastocyst stage in vitro. AG-haESCs can be derived by several rounds of Hoechst FACS based on DNA contents. The derivation of non-human primate AG-haESCs has not been reported yet.For many years, it has proven quite difficult to engineer site-specific mutations, knock-ins, and knock-outs in human ES or induced pluripotent stem (iPS) cells, and only a handful of genetically engineered lines have been created by conventional homologous recombination strategies⁶. However, recent advances in RNA-guided nuclease technology has led to a marked improvement in the efficiency of the knockout of genes in human pluripotent stem cells⁷, suggesting that it may be possible to create knock-out haploid non-human primate (NHP) ES cell lines that harbor specific disease genes and surrogate reporter readouts, and then to look for genetic complementation that could identify critical genes that could be potential drug targets. A library of individual NHP haploid ES cell lines that harbor a loss-of-function mutation across the entire NHP genome could find multiple uses in quickly identifying signaling pathways in differentiated cell types. Given recent advances in screening in human ES and iPS cell lines⁸, direct drug screening on the haploid monkey ES cell lines should also be possible. In addition, it will likely be possible to set up genome-wide screening to systematically identify entire network of genes that drive specific differentiation events, and early steps of primate organogenesis. If androgenetic NHP haploid cell lines can be developed (see Figure 1), a leap in the efficiency of the generation of monkey KO animal models could be envisioned over the long term. In this regard, the recent generation of chimeric monkeys⁹, as well as future technical advances related to this achievement, could become of significant interest.At the same time, the study indirectly raises the query as to the need for monkey model systems when the technology for genetic manipulation in the mouse is without peer, and human ES and iPS cell lines can now be easily generated and genetically manipulated. The recent pronouncement of the termination of NIH support for primate research (http://news.sciencemag.org/people-events/2013/06/nih-will-retire-most-research-chimps-end-many-projects), along with the growing awareness of the need to re-examine the need for NHP models, suggests that there must be very solid scientific grounds for pursuing NHP model systems in the future.In this regard, a growing body of evidence is now pointing to the lack of fidelity of mouse models of human disease to the in vivo human setting, a problem that has plagued cancer therapeutics for decades. Recently, the lack of predictability of human responses from models of murine sepsis has been cogently made¹⁰, and the divergence in the physiology of mice and humans, particularly in terms of metabolism and cardiovascular, are enormous. The complexity and scalability of primate versus murine organogenesis also may be an issue. For example, the human heart is 10 000 times larger than the murine, has a much larger diversity of cell types, and a level of tertiary morphology that is not found in the murine heart (for review see¹¹). Murine cardiogenesis is largely completed with 48 h, while human cardiogenesis occurs over months, and recent studies that suggest a much larger diversity and markedly extended period of proliferation of the family of heart progenitors in the human fetal versus murine heart¹². To date, there are no approved drugs that have come from genetically engineered murine models of cardiovascular (CV) disease, and the biggest CV drugs have actually been discovered based on human genetics (statins, PCSK9, etc.). The increased importance of CV side effects for new drugs in the diabetes space, as well as for other chronic diseases, points to the importance of their study in more sophisticated primate systems, as all these drugs (Avandia, Vioxx, etc.) had cleared conventional screening in rodent model systems. Given the above, we may have to put the Chinese Calendar on auto-repeat mode, as we enter the “Years of the Monkey” in this decade and the next.     

Biophysical correlates of lysophosphatidylcholine- and ethanol-mediated shape transformation and hemolysis of human erythrocytes. Membrane viscoelasticity and NMR measurement

The effects of monopalmitoylphosphatidylcholine (MPPC or lysophosphatidylcholine) and a series of short-chain primary alcohols (ethanol, 1-butanol and 1-hexanol) on cell shape, hemolysis, viscoelastic properties and membrane lipid packing of human red blood cells (RBCs) were studied. For MPPC, the effective membrane concentration to induce the formation of stage 3 echinocytes (8 x 10(6) molecules per cell) was one order of magnitude lower than that needed to induce 50% hemolysis (7 x 10(7) molecules per cell). In contrast, short-chain alcohols induced both shape changes and hemolysis within close concentration range (2.5 x 10(8) to 3.5 x 10(8) molecules per cell). Viscoelastic properties of the RBCs were studied by micropipette aspiration and correlated with shape change. Ethanol-treated RBCs showed a decrease in membrane elastic modulus and an increase in membrane viscosity in the recovery phase at the early stage of shape change. MPPC-treated cells showed the same type of viscoelastic changes, but these were not observed until the formation of stage 2 echinocytes. High-resolution solid-state 13C nuclear magnetic resonance technique was applied to study membrane lipid packing in the ghost membrane by following the chemical shift of hydrocarbon chains. Both MPPC and ethanol caused the 13C-NMR chemical shift to move upfield, indicating that membrane lipids were expanded due to the intercalation of these exogenous molecules. Using data obtained from model compounds, we convert values of chemical shift into a lipid packing parameter, i.e., number of gauche bonds for fatty acyl hydrocarbon chains. Approximately 10(8) interacting molecules per cell are required to induce a detectable change of lipid packing by both MPPC and ethanol. The results indicate that homolysis occurs at a smaller surface area for MPPC- than ethanol-treated RBCs. Our findings suggest that progressive changes in the molecular packing in the membrane lead eventually to hemolysis, but the mode responsible for shape transformation varies with these amphipaths.     

Human papillomavirus infection in oral papillary and verrucous lesions is a prognostic indicator of malignant transformation

Background: Recent studies have demonstrated an increase in the incidence of HPV-associated oral squamous cell carcinoma. The aim of this study was to investigate the presentation of HPV in verrucous and papillary lesions of the oral mucosa and the relationship with the prognosis of the patients. Methods: Fifty-three biopsy specimens from 31 patients were investigated by polymerase chain reaction using a consensus primer directed to the HPV L1 gene; this was followed by a confirmatory in situ hybridization to identify the HPV types. Result: Fifteen tumor biopsies (28.3%) were positive for the HPV L1 gene, but only 8 specimens (15.1%) were found to be positive using in situ hybridization. The positive rates of HPV L1 gene were 58.8% and 13.9% in malignant and benign verrucous lesions, respectively. HPV infection is independently associated with malignant transformation and disease-specific survival. Conclusion: The presence of HPV infection is relatively low; however, the clinical outcome of patients with HPV-positive papillary and verrucous lesions was poor.     

FUSE binding protein 1 interacts with untranslated regions of Japanese encephalitis virus RNA and negatively regulates viral replication

The untranslated regions (UTRs) located at the 5' and 3' ends of the Japanese encephalitis virus (JEV) genome, a positive-sense RNA, are involved in viral translation, the initiation of RNA synthesis, and the packaging of nascent virions. The cellular and viral proteins that participate in these processes are expected to interact with the UTRs. In this study, we used biotinylated RNA-protein pulldown and liquid chromatography-mass spectrometry/mass spectrometry (LC-MS/MS) analyses to identify that the far upstream element (FUSE) binding protein 1 (FBP1) binds with JEV 5' and 3' UTRs. The impact of FBP1 on JEV infection was determined in cells with altered FBP1 expression. JEV replication was enhanced by knockdown and reduced by the overexpression of FBP1, indicating a negative role for FBP1 in JEV infection. FBP1, a nuclear protein, was redistributed to the perinuclear region and appeared as cytoplasmic foci that partially colocalized with JEV RNA in the early stage of JEV infection. By using a JEV replicon reporter assay, FBP1 appeared to suppress JEV protein expression mediated by the 5' and 3' UTRs. Thus, we suggest that FBP1 binds with the JEV UTR RNA and functions as a host anti-JEV defense molecule by repressing viral protein expression.     

Effect of administered 20 beta-hydroxysteroid dehydrogenase on serum progesterone in the rat

Administration of 20 β-hydroxysteroid dehydrogenase from $\text{Streptomyces hydrogenans}$ to rats either intravenously or intraperitoneally results in decreases in serum progesterone.Detectable quantities of the enzyme were present in serum 2 days after intravenous injection. Intraperitoneal injections of 1.3 to 1.9 units of enzyme were effective in reducing serum progesterone over a longer period of time than the corresponding i.v. injections despite the failure of the enzyme to be absorbed into blood in detectable amounts; the serum concentration 2 hours after injection was 23% of that present before injection. The response was similar in diestrous and proestrous rats.     

Beyond make-or-buy: cross-company short-term capacity backup in semiconductor industry ecosystem

Since the uncertainty involved in demand forecast is increasingly amplified with the forecast lead-time, high-tech companies often suffer the risks of oversupply and shortage of capacity that will affect the profitability and growth. High-tech industries including semiconductor and TFT-LCD industries are capital-intensive, in which the capacity plan and corresponding capital investment decisions are critical due to demand fluctuation. Once the capacity is planned, the company may suffer the risks of either low capital-effectiveness due to low capacity utilization and capacity oversupply, or poor customer satisfaction caused by the capacity shortage. Most of the existing studies focused on solving the long-term capacity shortage issue through optimizing the capacity investment plan, or medium-term capacity plan to allocate demands among the wafer fabrication facilities (fabs) to balance the loading and product mix. Focusing on a real setting, this study proposed a systematic decision method to analyze short-term solutions of cross-company capacity backup between the companies in the semiconductor industry ecosystem. In particular, a game theory and decision tree analysis model was developed to support this decision. A case study was conducted with real data of semiconductor manufacturing companies in Taiwan for validation. The results have demonstrated practical viability of this approach. The approach suggested has been implemented in this company.     

BCRP/ABCG2 Inhibition Sensitizes Hepatocellular Carcinoma Cells to Sorafenib

The multikinase inhibitor, sorafenib (Nexavar®, BAY43-9006), which inhibits both the Raf/MEK/ERK pathway and several receptor tyrosine kinases (RTKs), has shown significantly therapeutic benefits in advanced hepatocellular carcinoma (HCC). However, not all HCC patients respond to sorafenib well and new therapeutic strategies to optimize the efficacy of sorafenib are urgently required. Overexpression of breast cancer resistance protein (BCRP/ABCG2) mediates the drug-efflux of several tyrosine kinase inhibitors (TKIs) to attenuate their efficacy. This study aimed to investigate the role of BCRP/ABCG2 in the sensitivity of HCC to sorafenib. Our data showed that BCRP/ABCG2 mediated the efflux of sorafenib. Co-treatment with a BCRP/ABCG2 inhibitor greatly augmented the cytotoxicity of sorafenib in HCC cells. Similar results were also achieved by the competitive inhibitor of BCRP/ABCG2, gefitinib, in combination with sorafenib. These results suggest not only that BCRP/ABCG2 is a potential predictor for the sorafenib sensitivity in HCC, but also that blockage of BCRP/ABCG2 may be a potential strategy to increase the response of HCC cells to sorafenib.     

<Emphasis Type="Italic">Sorting nexin 24</Emphasis> genetic variation associates with coronary artery aneurysm severity in Kawasaki disease patients

Background

The sorting nexin (SNX) family is involved in endocytosis and protein trafficking and plays multiple roles in various diseases. The role of SNX proteins in Kawasaki disease (KD) is not known. We attempted to test whether genetic SNX variation associates with the risk of coronary artery aneurysm (CAA) formation in KD.

Methods and results

Chi-square tests were used to identify SNX24 genetic variants associated with KD susceptibility and CAA formation in KD; models were adjusted for fever duration and time of first administration of intravenous immunoglobulin. We obtained clinical characteristics and genotypes from KD patients (76 with CAA and 186 without CAA) in a population-based retrospective KD cohort study (n?=?262). Clinical and genetic factors were associated with CAA formation in KD. In addition, endothelial cell inflammation was evaluated. Significant correlation was observed between KD with CAA complications and the rs28891 single-nucleotide polymorphism in SNX24. Patients with CC?+?CT genotypes had lesser CAA complications. In lipopolysaccharide-treated human umbilical vein endothelial cells, siRNA knockdown of SNX24 significantly decreased gene expression of the proinflammatory cytokines IL-1 beta, IL-6, and IL-8.

Conclusions

Polymorphisms in SNX24 may be used as genetic markers for the diagnosis and prognosis of CAA formation in KD.